Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

Arthritis is a common condition characterized by joint pain and stiffness. It’s crucial to debunk myths about its causes, age ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Diseases of the joints are known as arthritis. The term is derived from the Greek word that means exactly that: diseases of ...

Psoriasis is more than just a skin condition – it’s an autoimmune disorder that can manifest as scales, spots, or even ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

The classic signs of rheumatoid arthritis include pain, swelling, and stiffness of several joints. Persistent inflammation can lead to issues with mobility, fatigue, illness, and joint deformity over ...